On October 5, 2021 Redx Pharma (AIM: REDX), the drug discovery and development company focused on cancer and fibrosis, reported that it will host a Virtual R&D Day on 11 October 2021 at 1:00pm BST (8:00am EDT) (Press release, Redx Pharma, OCT 5, 2021, View Source [SID1234590806]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The R&D Day will include an update from the Company’s leadership team on Redx’s RXC004 programme and the potential of porcupine inhibition in Wnt-ligand driven colorectal, pancreatic and biliary cancers. There will also be an update on the Phase 1 study of RXC007, the Company’s selective ROCK2 inhibitor, being developed for idiopathic pulmonary fibrosis.

The programme includes presentations from leading experts:
· Professor Scott Kopetz, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center Presentation Title: ‘Potential of Porcupine Inhibition with RXC004 in Genetically Selected Patients with Metastatic MSS Colorectal Cancer’
· Professor Toby Maher, Professor of Medicine and Director of Interstitial Lung Disease, Keck School of Medicine, University of Southern California, Los Angeles Presentation Title: ‘Idiopathic Pulmonary Fibrosis’
· Professor Gisli Jenkins, Faculty of Medicine, National Heart & Lung Institute, Imperial College London
Presentation Title: ‘The Importance of ROCK in Fibrosis’
To register for the webcast, please email [email protected]. A recording of the webcast will be available on Redx’s website after the event

On October 5, 2021 Orum Therapeutics, a preclinical biotech pioneering the development of tumor-directed targeted protein degraders to improve cancer treatment, reported the appointment of Olaf Christensen, M.D., as Chief Medical Officer (Press release, Orum Therapeutics, OCT 5, 2021, View Source [SID1234590805]). He will lead the clinical development of Orum’s first-in-class targeted protein degraders from the company’s Antibody neoDegrader Conjugate (AnDC) platform.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We welcome Olaf to the team at this important time for Orum as we transition into a clinical stage biotech," said Sung Joo Lee, Ph.D., Founder and CEO, Orum Therapeutics. "Olaf brings extensive experience in oncology drug development, and we look forward to his leadership in realizing our vision of translating innovative science into breakthrough medicines."

"I am excited to join the Orum Therapeutics team, which works at the cutting edge of targeted protein degradation therapy," said Dr. Christensen. "Orum’s AnDC platform has the potential to steer the power of protein degraders with the precision of ADC technology in multiple indications with high unmet clinical need for the benefit of cancer patients. We are at the beginning of an exciting journey to bring this new class of drugs to patients."

Dr. Christensen has more than 15 years of experience in oncology drug development as an executive leader overseeing phase 1 through phase 4 clinical projects. Most recently, he was Vice President, Head of Oncology Global Clinical Development at EMD Serono, the healthcare business of Merck KGaA in the U.S. and Canada, where he was responsible for development of early to late stage pipeline compounds including immuno-oncology and targeted therapies. Earlier in his career, he worked at Bayer Pharmaceuticals and subsequently in the immuno-oncology clinical development group at Bristol Myers Squibb. He received his M.D. degree at the Albertus Magnus University Cologne, Germany, completed a dissertation in immunotherapy, and trained in oncology at the Clinic for Hematology/Oncology at the University of Heidelberg, Germany.

On October 5, 2021 Almac Sciences, a member of the Almac Group, reported expanding collaborations with University College Dublin (UCD) for flow based-oxidation approaches through a co-founded PhD scholarship (Press release, Almac, OCT 5, 2021, View Source [SID1234590798]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Almac Sciences and Dr Marcus Baumann have an already well-established partnership through a Science Foundation Ireland (SFI) Industry Fellowship on the Continuous Biocatalysed Chemicals (CATCH) project which was publicised in 2020. Together the team has published six peer-reviewed papers focusing on the development of continuous flow approaches to demonstrate the synergies between technology platforms, such as flow chemistry and biocatalysis. Highlights include development of Curtius rearrangements under flow and demonstration of the synergies attainable with biocatalysis with a novel enzyme mediated purification strategy.

The new PhD scholarship is co-funded by Almac Sciences and the SFI Research Centre for Pharmaceuticals (SSPC) over the next 4 years and will investigate flow-based oxidation processes. This year’s student, Niamh Disney, will undertake industry placements within Almac, offering an immersive experience on which she will build key transferable skills and gain insight into critical decision-making for flow processes on an industrial scale.

Lead academic at UCD, Dr Marcus Baumann said "I am very excited to continue to work with Almac Sciences and publish further as we investigate novel oxidative approaches under continuous flow. It affords further extension of my research portfolio in industrially relevant fields."

This latest development demonstrates further Almac’s commitment to technology innovation as it continues to expand service offerings for the pharmaceutical, biotechnology, life sciences and fine chemical sectors following a £325,000 investment, specifically in flow capabilities.

Dr Megan Smyth, Technical Leader, Almac Sciences commented: "This PhD further intensifies our collaboration with the Baumann group at UCD and we look forward to working with Marcus and Niamh. Through close collaboration, and time with us at our state-of-the-art facilities, Niamh will gain a valuable insight into industrially relevant target transformations and I wish her every success with her studies."

On October 4, 2022 SomaGenics presented its novel wound healing therapeutic based on the sshRNA RNAi technology to the NIH Innovation Conference (Press release, SomaGenics, OCT 4, 2021, https://www.somagenics.com/news/2022/4/15/somagenics-presents-at-the-nih-innovation-conference-and-the-life-science-summit-company-showcase [SID1234612316]). SomaGenics also presented to investors at the Life Sciences Summit, held November 9-10, 2021.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As a result of its NIH SBIR funding for the wound healing program, SomaGenics was subsidized by the NIH SEED program to present free of charge to these life sciences investor conferences and, with other such participants, received valuable coaching and feedback from the venture capital investment community.

On October 4, 2021 Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient’s body, reported three poster presentations at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021 (Press release, Cue Biopharma, OCT 4, 2021, View Source [SID1234608269]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Title: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer
Poster #: 438
Presenter: Dr. Sara I. Pai, M.D., Ph.D., associate professor of surgery, Division of Gastrointestinal and Oncologic Surgery; Director, Translational Research in Head and Neck Cancer Massachusetts General Hospital, Boston MA
Date: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.–8:30 p.m. EST

Title: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients
with WT1+ malignancies
Poster #: 720
Presenter: Dr. Christie Zhang, Ph.D., senior scientist, discovery and translational immunology, Cue Biopharma
Date: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.–8:30 p.m. EST

Title: Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platforms
Poster #: 793
Presenter: Raymond J. Moniz, associate director, discovery and translational immunology, Cue Biopharma
Date: Friday, November 12, 2021, Poster Hall (Hall E) 7 a.m.–8:30 p.m. EST

ePosters will be on display on the SITC (Free SITC Whitepaper) 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

"We look forward to presenting additional preclinical and clinical data that continues to validate the therapeutic potential of our IL-2 based CUE-100 series Immuno-STAT platforms and biologics," said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. "We believe the data demonstrated in these posters show great promise in selective and specific tumor targeting for the treatment of multiple cancers and other life-threatening diseases."

About the CUE-100 Series
The CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About SITC (Free SITC Whitepaper)
The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC (Free SITC Whitepaper) aims to one day make the word "cure" a reality for cancer patients everywhere.

Currently, SITC (Free SITC Whitepaper) has more than 4,650 members who represent over 35 medical specialties in 63 countries around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC (Free SITC Whitepaper) brings together all aspects of the cancer immunology and immunotherapy community.